Oct 8, 2021 This Week in Cardiology Podcast

Two NEJM papers on mRNA-related myocarditis, AF and stroke, intensifying BP meds, and CCTA and high-sensitivity troponin are the topics John Mandrola, MD, covers in this week's podcast. To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I -- Vaccine-Induced Myocarditis

New Reports Help Nail Down Myocarditis Risk With COVID-19 Vaccine

https://www.staging.medscape.com/viewarticle/960537

• Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel

https://www.nejm.org/doi/full/10.1056/NEJMoa2109730

• Myocarditis after Covid-19 Vaccination in a Large Health Care Organization

https://www.nejm.org/doi/full/10.1056/NEJMoa2110737

II – AF and Stroke

AF a Stroke Cause or Innocent Bystander? The Debate Continues

https://www.medscape.com/viewarticle/960224

• Temporal Association Between Episodes of Atrial Fibrillation and Risk of Ischemic Stroke

https://jamanetwork.com/journals/jamacardiology/fullarticle/2784332

• It's Time to Rethink (and Retrial) Our Framework for Stroke Prevention in Atrial Fibrillation

https://jamanetwork.com/journals/jamacardiology/fullarticle/2784335

III- Intensification of BP Control

Adding New Hypertensive May Be More Potent Than Upping Doses

https://www.medscape.com/viewarticle/960454

• Adding a New Medication Versus Maximizing Dose to Intensify Hypertension Treatment in Older Adults

https://doi.org/10.7326/M21-1456

IV- Hs-troponin and CAD

Troponin Levels Tied to Increased CAD Risk, May Guide Imaging /viewarticle/960146

• Troponin-Guided Coronary Computed Tomographic Angiography After Exclusion of Myocardial Infarction

https://doi.org/10.1016/j.jacc.2021.07.055

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact

[email protected]